Sarepta Therapeutics
Sarepta Therapeutics

Sarepta Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

$1.8B

Market Cap • 11/10/2026

1980

(46 years)

Founded

1997

(29 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,2

P/S

0,9

P/EBITDA

—

P/OCF

9,5

P/FCF

10

P/E

—

BVPS

14,3

EPS

0,1

Market Cap

Market Cap

1,8B

EV

1,9B

EV/Revenue

1

EV/EBITDA

-115,6

EV/EBIT

-39,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0,3%

Total Yield

0,3%

Payout

0%

Retained Earnings

-4,6B

Profitability

Gross Margin

56,8%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

33,4%

Capex/Revenue

0,5%

Capex/D&A

28,5%

Capex/OCF

4,9%

SBC/OCF

20,1%

% PPE

13,8%

% Goodwill

0%

ROE

1%

ROIC

—

Growth

CAGR Revenue 5Y

24,8%

CAGR Op. Income 5Y

-37,8%

CAGR EPS 5Y

-25,9%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,5

Quick Ratio

1,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium